Advances in the application of C5 Inhibitors for sensitized waitlisted candidates in kidney transplantation
10.3760/cma.j.cn421203-20241030-00220
- VernacularTitle:补体成分5抑制剂在致敏肾移植受者的应用进展
- Author:
Xiaoqiang WU
1
;
Xiangyong TIAN
1
;
Xueyu LI
1
;
Qilin LI
1
;
Zhiwei WANG
1
;
Tianzhong YAN
1
Author Information
1. 郑州大学人民医院泌尿外科 河南省人民医院，郑州 450003
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Human leukocyte antigen;
Priming;
C5;
Inhibitor
- From:
Chinese Journal of Organ Transplantation
2025;46(8):587-591
- CountryChina
- Language:Chinese
-
Abstract:
This article reviews the application and future prospects of complement component 5 (C5) inhibitors in kidney transplantation for sensitized recipients. Kidney transplantation significantly improves the survival and quality of life for patients with end-stage kidney disease. However, donor kidney shortages and human leukocyte antigen (HLA) sensitization are major obstacles. HLA-sensitized candidates, particularly highly sensitized ones, face a significantly elevated risk of post-transplant rejection due to pre-existing HLA antibodies. Eculizumab, a terminal complement inhibitor, inhibits rejection by preventing the cleavage of C5 into C5a and C5b, thus blocking the formation of the membrane attack complex and suppressing complement-dependent cytotoxicity.
